Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AVR
stocks logo

AVR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.540
sliders
Low
15.00
Averages
17.50
High
20.00
Current: 4.540
sliders
Low
15.00
Averages
17.50
High
20.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Anteris Technologies Global Corp (AVR.O) is -2.19, compared to its 5-year average forward P/E of -2.32. For a more detailed relative valuation and DCF analysis to assess Anteris Technologies Global Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.32
Current PE
-2.19
Overvalued PE
-1.56
Undervalued PE
-3.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.68
Current EV/EBITDA
-1.78
Overvalued EV/EBITDA
-0.76
Undervalued EV/EBITDA
-2.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
36.27
Current PS
20.94
Overvalued PS
58.10
Undervalued PS
14.44
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

AVR News & Events

Events Timeline

(ET)
2025-11-17
06:08:27
Anteris Technologies Showcases Data from 100 Patients with DurAVR(R) THV at PCR London
select
2025-11-03 (ET)
2025-11-03
07:17:21
Anteris Technologies granted FDA approval to start PARADIGM trial
select
2025-10-28 (ET)
2025-10-28
18:18:33
Anteris Technologies shares clinical results for DurAVR THV in patients
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13Newsfilter
Anteris Reports Third Quarter 2025 Results

  • Third Quarter 2025 Highlights: Anteris Technologies reported significant progress in regulatory approvals for the PARADIGM Trial, with FDA approval for U.S. recruitment and the first patients treated in Denmark following European regulatory clearance.

  • Financial Overview: The company reported net operating cash outflows of $59.3 million for the nine months ending September 30, 2025, primarily due to clinical, regulatory, and manufacturing activities related to the PARADIGM Trial.

  • DurAVR® THV Commercialization: Anteris is advancing the commercialization of its DurAVR® Transcatheter Heart Valve, with ongoing preparations for the PARADIGM Trial, including site readiness and investigator training.

  • About the PARADIGM Trial: The trial aims to evaluate the safety and effectiveness of the DurAVR® THV compared to existing transcatheter aortic valve replacements, enrolling approximately 1,000 patients across the U.S., Europe, and Canada.

[object Object]
Preview
9.0
11-03NASDAQ.COM
Anteris Secures FDA Authorization for PARADIGM Trial

  • FDA Approval: Anteris has received FDA approval to start the PARADIGM clinical trial for the DurAVR Transcatheter Heart Valve, aimed at patients with severe calcific aortic stenosis.

  • Trial Purpose: The PARADIGM Trial is intended to gather clinical evidence to support a future Premarket Approval (PMA) submission to the FDA, with CE Mark approval expected to proceed concurrently.

  • Market Reaction: Following the announcement, Anteris shares increased by 3% in pre-market trading on Monday.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.0
11-03Newsfilter
FDA Grants Approval for Anteris's Global Pivotal Trial of DurAVR® THV (the "PARADIGM Trial")

  • FDA Approval for PARADIGM Trial: Anteris has received FDA approval to initiate the PARADIGM Trial, a global clinical study evaluating the safety and effectiveness of the DurAVR® Transcatheter Heart Valve in patients with severe calcific aortic stenosis.

  • Trial Design and Objectives: The trial will enroll approximately 1000 patients across the U.S., Europe, and Canada, comparing the DurAVR® THV to commercially available TAVR devices, with a focus on non-inferiority regarding all-cause mortality, stroke, and cardiovascular hospitalization at one year.

  • Innovative Heart Valve Technology: The DurAVR® THV is the first biomimetic valve designed to replicate the performance of a healthy aortic valve, utilizing Anteris' patented ADAPT® tissue technology, which has been clinically used for over a decade.

  • Company Background: Anteris Technologies is a global structural heart company focused on developing advanced medical devices for heart function restoration, with a significant presence in both Australia and the U.S.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Anteris Technologies Global Corp (AVR) stock price today?

The current price of AVR is 4.54 USD — it has increased 1.79 % in the last trading day.

arrow icon

What is Anteris Technologies Global Corp (AVR)'s business?

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

arrow icon

What is the price predicton of AVR Stock?

Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Anteris Technologies Global Corp (AVR)'s revenue for the last quarter?

Anteris Technologies Global Corp revenue for the last quarter amounts to 429.00K USD, decreased -44.21 % YoY.

arrow icon

What is Anteris Technologies Global Corp (AVR)'s earnings per share (EPS) for the last quarter?

Anteris Technologies Global Corp. EPS for the last quarter amounts to -0.62 USD, increased 1.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for Anteris Technologies Global Corp (AVR)'s fundamentals?

The market is revising Downward the revenue expectations for Anteris Technologies Global Corp. (AVR) for FY2025, with the revenue forecasts being adjusted by -14.61% over the past three months. During the same period, the stock price has changed by 9.13%.
arrow icon

How many employees does Anteris Technologies Global Corp (AVR). have?

Anteris Technologies Global Corp (AVR) has 136 emplpoyees as of December 05 2025.

arrow icon

What is Anteris Technologies Global Corp (AVR) market cap?

Today AVR has the market capitalization of 187.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free